These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34147205)

  • 21. Co-Crystals for Generic Pharmaceuticals: An Outlook on Solid Oral Dosage Formulations.
    Rajendran MAP; Allada R; Sajid SS
    Recent Adv Drug Deliv Formul; 2021; 15(1):15-36. PubMed ID: 34602030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids.
    Shah B; Kakumanu VK; Bansal AK
    J Pharm Sci; 2006 Aug; 95(8):1641-65. PubMed ID: 16802362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melt extrusion with poorly soluble drugs.
    Shah S; Maddineni S; Lu J; Repka MA
    Int J Pharm; 2013 Aug; 453(1):233-52. PubMed ID: 23178213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for new pharmaceutical solid forms using mechanochemistry: A practical guide.
    Hasa D; Jones W
    Adv Drug Deliv Rev; 2017 Aug; 117():147-161. PubMed ID: 28478084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of pharmaceutically relevant materials at the solid state employing chemometrics methods.
    Calvo NL; Maggio RM; Kaufman TS
    J Pharm Biomed Anal; 2018 Jan; 147():538-564. PubMed ID: 28666554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient co-crystal screening using solution-mediated phase transformation.
    Zhang GG; Henry RF; Borchardt TB; Lou X
    J Pharm Sci; 2007 May; 96(5):990-5. PubMed ID: 17455356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Islatravir Case Study for Enhanced Screening of Thermodynamically Stable Crystalline Anhydrate Phases in Pharmaceutical Process Development by Hot Melt Extrusion.
    Skomski D; Varsolona RJ; Su Y; Zhang J; Teller R; Forster SP; Barrett SE; Xu W
    Mol Pharm; 2020 Aug; 17(8):2874-2881. PubMed ID: 32511923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients.
    Yadav AV; Shete AS; Dabke AP; Kulkarni PV; Sakhare SS
    Indian J Pharm Sci; 2009 Jul; 71(4):359-70. PubMed ID: 20502540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can pharmaceutical co-crystals provide an opportunity to modify the biological properties of drugs?
    Dalpiaz A; Pavan B; Ferretti V
    Drug Discov Today; 2017 Aug; 22(8):1134-1138. PubMed ID: 28130117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
    Heinz A; Strachan CJ; Gordon KC; Rades T
    J Pharm Pharmacol; 2009 Aug; 61(8):971-88. PubMed ID: 19703341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Examination of Water Vapor Sorption by Multicomponent Crystalline and Amorphous Solids and Its Effects on Their Solid-State Properties.
    Newman A; Zografi G
    J Pharm Sci; 2019 Mar; 108(3):1061-1080. PubMed ID: 30391302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystallization Kinetics of an Amorphous Pharmaceutical Compound Using Fluorescence-Lifetime-Imaging Microscopy.
    Rautaniemi K; Vuorimaa-Laukkanen E; Strachan CJ; Laaksonen T
    Mol Pharm; 2018 May; 15(5):1964-1971. PubMed ID: 29584954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.
    Ticehurst MD; Marziano I
    J Pharm Pharmacol; 2015 Jun; 67(6):782-802. PubMed ID: 25677227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The construction, prediction and measurement of co-crystal ternary phase diagrams as a tool for solvent selection.
    Holaň J; Stěpánek F; Billot P; Ridvan L
    Eur J Pharm Sci; 2014 Oct; 63():124-31. PubMed ID: 24995701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous manufacturing of co-crystals: challenges and prospects.
    Chavan RB; Thipparaboina R; Yadav B; Shastri NR
    Drug Deliv Transl Res; 2018 Dec; 8(6):1726-1739. PubMed ID: 29352367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals.
    Healy AM; Worku ZA; Kumar D; Madi AM
    Adv Drug Deliv Rev; 2017 Aug; 117():25-46. PubMed ID: 28342786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influences of Crystal Anisotropy in Pharmaceutical Process Development.
    Hadjittofis E; Isbell MA; Karde V; Varghese S; Ghoroi C; Heng JYY
    Pharm Res; 2018 Mar; 35(5):100. PubMed ID: 29556822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
    Srinarong P; de Waard H; Frijlink HW; Hinrichs WL
    Expert Opin Drug Deliv; 2011 Sep; 8(9):1121-40. PubMed ID: 21722000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering of pharmaceutical materials: an industrial perspective.
    Chow K; Tong HH; Lum S; Chow AH
    J Pharm Sci; 2008 Aug; 97(8):2855-77. PubMed ID: 17943933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions.
    Ricarte RG; Van Zee NJ; Li Z; Johnson LM; Lodge TP; Hillmyer MA
    Mol Pharm; 2019 Oct; 16(10):4089-4103. PubMed ID: 31487183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.